Actualités Quest PharmaTech Inc - QPT | Actions TSX Venture Exchange

Quest PharmaTech Announces Results from AGM

EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the...

Quest PharmaTech Receives U.S. $2 Million for its Immuno-Photodynamic Therapy Assets

Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”), a pharmaceutical company developing and commercializing products to improve...

Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creato...

Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creator of COLD...

Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer

Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer PR Newswire EDMONTON, June...

Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford Univer...

Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford University; Researchers to...

Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for C...

Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer PR...

Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti ...

Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti - PSA IgE...

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Ca...

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and...

Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Can...

Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Cancer PR...

Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy

Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy PR Newswire EDMONTON, July 10...

Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States

Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States PR Newswire EDMONTON, June 14, 2012...

Quest PharmaTech Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs

Quest PharmaTech Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs PR Newswire EDMONTON, June 5...

Quest PharmaTech Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based o...

Quest PharmaTech Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based on Nanotechnology PR...

Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)

Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011) PR Newswire EDMONTON...

Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherap...

Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherapy for the Treatment...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quest PharmaTech Inc (QPT)

Outils de qualité professionnelle, pour des investisseurs individuels.

QPT Actualités

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Receives U.S. $2 Million for its Immuno-Photodynamic Therapy Assets

Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creato...

Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer

Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford Univer...

Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for C...

Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti ...

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Ca...

Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Can...

Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy

Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States

Quest PharmaTech Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs

Quest PharmaTech Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based o...

Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)

Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherap...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Quest PharmaTech Inc (QPT) Actualités

Quest PharmaTech Inc (QPT)

Outils de qualité professionnelle, pour des investisseurs individuels.

QPT Actualités

Quest PharmaTech Announces Results from AGM

Quest PharmaTech Receives U.S. $2 Million for its Immuno-Photodynamic Therapy Assets

Quest PharmaTech to Market and Distribute Premium Anti-Wrinkle Skin Care Product, Bellus Skin™; Dr. Jacqueline Shan, Creato...

Quest PharmaTech Completes Patient Enrollment in Phase IIb Study of Oregovomab for the Immunotherapy of Ovarian Cancer

Quest PharmaTech strengthens its Antibody Immunotherapy Technology by licensing anti-MUC1 IgE Technology from Stanford Univer...

Quest PharmaTech Establishes Joint Venture with Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for C...

Quest PharmaTech Signs Exclusive License Agreement with UCLA for anti - PSA IgE Technology; UCLA researchers to present anti ...

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Ca...

Quest PharmaTech Acquires Immunoglobulin E Technology to Strengthen its Combination Therapy Approach for the Treatment of Can...

Quest PharmaTech Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy

Quest PharmaTech Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States

Quest PharmaTech Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs

Quest PharmaTech Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based o...

Quest PharmaTech Announces Oregovomab Presentation at Biennial Meeting of Asian Society of Gynecologic Oncology (ASGO 2011)

Quest PharmaTech Announces Allowance of US Patent for the use of Immunotherapeutic Antibodies in Combination with Chemotherap...

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application